Obiettivo Animals and bacteria have been working together for about as long as they have co-existed, long before the advent of mankind. The bodies of our ancient ancestors offered protected, nutrient-rich habitats for bacteria. In return, animals could take an evolutionary short-cut to developing new capabilities by ‘borrowing’ bacterial genes. Indeed, when gut bacteria assist with the digestion of e.g. dietary fiber, the resulting metabolites will subsequently exert an influence on an intricate network of host molecular pathways. Gut microbiota, in addition to host genetics, can therefore constitute a major factor in the etiology of complex disorders, ranging from obesity, cardiovascular disease, autoimmune disease (multiple sclerosis, rheumatoid arthrosis), inflammation (inflammatory bowel disease, Crohn’s) to neurological conditions. Although such a key role for the human microbiomes had been postulated for some time, many details on the delicate interplay between flora and host remained unknown, largely because suitable methods for uncovering these host-guest interactions were simply not available. These technological barriers keep the diagnostic and therapeutic potential of the microbiome largely untapped. In this project, we will validate the FLUROCODE genomic mapping technology as an alternative to shotgun sequencing and amplicon based techniques for microbiome studies. This will extend the benefits of genomic mapping techniques to complex sample analysis. Through a head-to-head comparison with the state of the art in metagenomic analysis, the POC data will serve as a key enabler for the transfer of the technology platform into a separate venture, working towards diagnostic applications and developing METAMAPPER based microbiome screening as a routine medical tool. The METAMAPPER microbiome readout technology is be perfectly placed to be part of the evolution of microbiome analysis to clinical application. Campo scientifico natural sciencesbiological sciencesmicrobiologybacteriologymedical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineneurologymultiple sclerosismedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health sciencesclinical medicinecardiologycardiovascular diseases Programma(i) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Argomento(i) ERC-2017-PoC - ERC-Proof of Concept Invito a presentare proposte ERC-2017-PoC Vedi altri progetti per questo bando Meccanismo di finanziamento ERC-POC - Proof of Concept Grant Istituzione ospitante KATHOLIEKE UNIVERSITEIT LEUVEN Contribution nette de l'UE € 149 875,00 Indirizzo OUDE MARKT 13 3000 Leuven Belgio Mostra sulla mappa Regione Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 149 875,00 Beneficiari (1) Classifica in ordine alfabetico Classifica per Contributo netto dell'UE Espandi tutto Riduci tutto KATHOLIEKE UNIVERSITEIT LEUVEN Belgio Contribution nette de l'UE € 149 875,00 Indirizzo OUDE MARKT 13 3000 Leuven Mostra sulla mappa Regione Vlaams Gewest Prov. Vlaams-Brabant Arr. Leuven Tipo di attività Higher or Secondary Education Establishments Collegamenti Contatta l’organizzazione Opens in new window Sito web Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 149 875,00